ICON plc (ICLR)

148.58
1.30 0.91
NASDAQ : Health Technology
Prev Close 147.24
Open 147.47
Day Low/High 146.78 / 149.12
52 Wk Low/High 118.10 / 165.13
Volume 65.15K
Avg Volume 227.60K
Exchange NASDAQ
Shares Outstanding 54.08M
Market Cap 7.84B
EPS 6.00
P/E Ratio 21.88
Div & Yield N.A. (N.A)

Latest News

ICON Plc To Present At Baird's 2019 Global Healthcare Conference

ICON Plc To Present At Baird's 2019 Global Healthcare Conference

ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Dr.

ICON Announces The Appointment Of Ms. Julie O'Neill To Board Of Directors And Confirms The Retirement Of Professor Dermot Kelleher And Mr. Declan McKeon As Non-Executive Directors

ICON Announces The Appointment Of Ms. Julie O'Neill To Board Of Directors And Confirms The Retirement Of Professor Dermot Kelleher And Mr. Declan McKeon As Non-Executive Directors

ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Ms.

ICON Shareholders Vote In Favour Of All Resolutions At Its Annual General Meeting

ICON Shareholders Vote In Favour Of All Resolutions At Its Annual General Meeting

ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that all resolutions at the Annual General Meeting of the Company (AGM) held on July...

ICON And DIA Driving Insights To Action With DIA Live 2019

ICON And DIA Driving Insights To Action With DIA Live 2019

ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that it will present DIA Live - a social media aggregation site...

ICON's Acquisition Of MeDiNova Research

ICON's Acquisition Of MeDiNova Research

ICON plc , (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has acquired a majority shareholding in MeDiNova Research, a...

ICON Awarded Clinical Research Team Of The Year And Best In Health Economics And Outcomes Research

ICON Awarded Clinical Research Team Of The Year And Best In Health Economics And Outcomes Research

ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has been awarded the Clinical Research Team of the Year (with Eli...

ICON Launches New Patient Engagement Platform To Support Improved Patient Experience And Enrollment In Clinical Trials

ICON Launches New Patient Engagement Platform To Support Improved Patient Experience And Enrollment In Clinical Trials

ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced the release of its web based patient engagement platform, to...

ICON Reports First Quarter 2019 Results

ICON Reports First Quarter 2019 Results

ICON plc (NASDAQ:ICLR) , a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2019.

ICON Wins Multiple Categories In 2019 CRO Leadership Awards

ICON Wins Multiple Categories In 2019 CRO Leadership Awards

ICON plc, (NASDAQ: ICLR) a global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, has won awards across several categories in the annual CRO Leadership Awards.

ICON Reports Fourth Quarter And Full Year 2018 Results

ICON Reports Fourth Quarter And Full Year 2018 Results

ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the fourth quarter and full year ended December 31, 2018.

ICON Issues Financial Guidance For Full Year 2019

ICON Issues Financial Guidance For Full Year 2019

ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced its financial guidance for the year ended December 31, 2019.

ICON Wins Pharma Contract Services Company Of The Year At The Pharma Industry Awards 2018

ICON Wins Pharma Contract Services Company Of The Year At The Pharma Industry Awards 2018

ICON plc, (NASDAQ: ICLR) a global provider of drug development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded Pharma Contract Services Company of the Year for the second time.

ICON Reports Third Quarter 2018 Results

ICON Reports Third Quarter 2018 Results

ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the third quarter ended September 30, 2018.

ICON Announces Release Of ADDPLAN® Neo

ICON Announces Release Of ADDPLAN® Neo

(NASDAQ: ICLR) a global provider of drug development services to the pharmaceutical, biotechnology and medical device industries, today announced the release of ADDPLAN® neo, providing an advanced validated integrated technology platform for design,...

ICON Confirms Retirement Of Co-Founder Dr. Ronan Lambe

ICON Confirms Retirement Of Co-Founder Dr. Ronan Lambe

ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today confirmed, that Dr.

ICON Reports Second Quarter 2018 Results

ICON Reports Second Quarter 2018 Results

ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the second quarter ended June 30, 2018.

ICON Is Collaborating With Practice Fusion, Inc. To Advance Health Research

ICON Is Collaborating With Practice Fusion, Inc. To Advance Health Research

ICON plc, (NASDAQ: ICLR) a global provider of drug development services to the pharmaceutical, biotechnology and medical device industries, today announced that it is working with Practice Fusion to leverage active patient data in support of health...

ICON Enhances Endpoint Adjudication Services Using AG Mednet Advanced Technology

ICON Enhances Endpoint Adjudication Services Using AG Mednet Advanced Technology

ICON plc (NASDAQ: ICLR), a global provider of drug development and commercialisation solutions and services, today announced it has signed an agreement with AG Mednet to use Judi, a comprehensive electronic endpoint adjudication system to manage workflow...

ICON Launches FIRECREST Financial Disclosure To Reduce Administrative Costs And Increase Regulatory Compliance

ICON Launches FIRECREST Financial Disclosure To Reduce Administrative Costs And Increase Regulatory Compliance

ICON plc, (NASDAQ: ICLR) a global provider of drug development and commercialisation solutions and services, today announced the launch of FIRECREST Financial Disclosure, an innovative digital solution that increases the efficiency and compliance of...

ICON Named By Forbes As One Of The Best Employers In America

ICON Named By Forbes As One Of The Best Employers In America

ICON plc , (NASDAQ: ICLR) a global provider of drug development and commercialisation solutions and services, today announced that it has been included in Forbes magazine's America's Best Employers list for 2018.

Saama Technologies And ICON Commercialization And Outcomes Partner To Unlock The Value Of Real World Evidence (RWE)

Saama Technologies And ICON Commercialization And Outcomes Partner To Unlock The Value Of Real World Evidence (RWE)

Saama Technologies, a leading clinical and health data analytics company, and ICON plc (NASDAQ: ICLR), a global provider of drug development and commercialization solutions and services, have partnered to accelerate the use of Real World Evidence (RWE)...

ICON Announces Clinical Research Partnership With DuPage Medical Group

ICON Announces Clinical Research Partnership With DuPage Medical Group

ICON plc (NASDAQ: ICLR), a global provider of drug development and commercialisation solutions and services, today announced that PMG Research, Inc.

ICON Sponsors Industry-Wide Clinical Trials Survey To Support Transforming Trials Initiative

ICON Sponsors Industry-Wide Clinical Trials Survey To Support Transforming Trials Initiative

ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the results from a new survey of pharmaceutical executives and professionals by ICON...

ICON Reports First Quarter 2018 Results

ICON Reports First Quarter 2018 Results

ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2018.

ICON Announces Launch Of Government And Public Health Solutions To Support Global Public Health

ICON Announces Launch Of Government And Public Health Solutions To Support Global Public Health

ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the rebranding of their acquired ClinicalRM...

ICON Reports Fourth Quarter And Full Year 2017 Results

ICON Reports Fourth Quarter And Full Year 2017 Results

ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the fourth quarter...

ICON Issues Financial Guidance For Full Year 2018

ICON Issues Financial Guidance For Full Year 2018

ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced its financial guidance for the year ended...

ICON Appoints Dr. James Cummings As President Of ClinicalRM

ICON Appoints Dr. James Cummings As President Of ClinicalRM

ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Dr.

TheStreet Quant Rating: A- (Buy)